Kocoglu Mehmet, Badros Ashraf
Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, MD 21201, USA.
Pharmaceuticals (Basel). 2016 Jan 14;9(1):3. doi: 10.3390/ph9010003.
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic research efforts towards better understanding of normal and missing immune surveillence in myeloma have led to development of new strategies and therapies that require the engagement of the immune system. Many of these treatments are under clinical development and have already started providing encouraging results. We, for the second time in the last two decades, are about to witness another shift of the paradigm in the management of this ailment. This review will summarize the major approaches in myeloma immunotherapies.
多发性骨髓瘤是第二常见的血液系统恶性肿瘤。在过去二十年中，随着蛋白酶体抑制剂和免疫调节药物等新型药物引入临床实践，这种疾病的治疗发生了很大变化。为更好地理解骨髓瘤中正常和缺失的免疫监视而进行的基础研究努力，已导致开发出需要免疫系统参与的新策略和疗法。其中许多治疗方法正在临床开发中，并且已经开始取得令人鼓舞的结果。在过去二十年中，我们第二次即将见证这种疾病治疗模式的又一次转变。本综述将总结骨髓瘤免疫治疗的主要方法。
